Why Tirzepatide Represents a Different Class From Earlier GLP-1 Peptides
Tirzepatide (LY3298176) was the first compound to demonstrate that co-agonism of the GIP receptor alongside the GLP-1 receptor produces synergistic metabolic effects that exceed those of GLP-1 receptor agonism alone. This "twincretin" mechanism underpins tirzepatide's superiority over semaglutide in head-to-head comparisons and makes it pharmacologically distinct from all earlier GLP-1 class compounds.
The GIPR co-agonism in tirzepatide enhances insulin sensitisation in adipocytes, modulates lipid metabolism, and appears to potentiate GLP-1R-mediated satiety signalling in the hypothalamus. The result is a more complete metabolic intervention than GLP-1 receptor agonism alone can achieve — reflected in SURMOUNT-1's 20.9% body weight reduction, which substantially exceeded STEP 1 semaglutide's 14.9% in comparable populations.
Compound profile Name: Tirzepatide (LY3298176) · Class: Dual GLP-1/GIP receptor agonist (twincretin) · Half-life: ~5 days · Dosing: Once weekly subcutaneous injection · Phase 3: Four completed SURMOUNT trials · TGA approved brand: Mounjaro (prescription only, distinct from research-grade supply)
SURMOUNT Programme: Key Clinical Trial Data
Four SURMOUNT trials have been completed as of 2026, making tirzepatide one of the most extensively studied compounds in the metabolic peptide class:
| Trial | Population | Duration | Key outcome |
|---|---|---|---|
| SURMOUNT-1 | Obesity, no T2D | 72 weeks | 20.9% mean weight loss at 15mg |
| SURMOUNT-2 | Obesity + T2D | 72 weeks | 15.7% weight loss at 15mg in T2D population |
| SURMOUNT-3 | Obesity + intensive lifestyle | 72 weeks | 26.6% weight loss (tirzepatide phase after lifestyle lead-in) |
| SURMOUNT-4 | Obesity — maintenance after initial loss | 52 weeks | 5.5% regain vs 14% with placebo after switching |
SURMOUNT-1 remains the reference trial: 20.9% mean body weight reduction at 15mg over 72 weeks in adults with obesity (BMI ≥30) without type 2 diabetes. Approximately 37% of participants in the 15mg cohort achieved ≥25% body weight reduction — a response magnitude not seen with any previous GLP-1 class compound. SURMOUNT-MMO (cardiovascular outcomes trial) is ongoing as of 2026.
Tirzepatide Dosing and Escalation Schedule
The SURMOUNT-1 dosing schedule began at 2.5mg/week and escalated in 4-week steps to the target maintenance dose. All participants started at the same 2.5mg initial dose regardless of their assigned target dose cohort:
| Cohort | Weeks 1–4 | Weeks 5–8 | Weeks 9–12 | Weeks 13–16 | Maintenance |
|---|---|---|---|---|---|
| 5mg | 2.5mg | 5mg | 5mg | 5mg | 5mg |
| 10mg | 2.5mg | 5mg | 7.5mg | 10mg | 10mg |
| 15mg | 2.5mg | 5mg | 7.5mg | 10mg | 15mg (from week 17) |
The 4-week hold at each escalation step is the minimum duration from SURMOUNT-1 methodology. Dose holds (remaining at the current dose for an additional period if GI events are significant) were permitted in the trial protocol. The 2.5mg starting dose is notably lower than retatrutide's 0.5mg starting dose — this reflects tirzepatide's dose range starting at a higher absolute level rather than a more aggressive initial exposure.
Reconstitution Protocol for Australian Researchers
RetaLABS Tirzepatide is supplied lyophilised in 30mg vials. Reconstitute with bacteriostatic water to achieve the desired concentration.
30mg vial + 3mL bacteriostatic water = 10 mg/mL:
| Weekly dose | Injection volume | U100 syringe units | Doses per 30mg vial |
|---|---|---|---|
| 2.5mg | 0.25 mL | 25 units | 12 |
| 5mg | 0.50 mL | 50 units | 6 |
| 7.5mg | 0.75 mL | 75 units | 4 |
| 10mg | 1.00 mL | 100 units | 3 |
| 15mg | 1.50 mL | 150 units | 2 |
Use bacteriostatic water — not sterile water — for reconstitution. BAC water extends reconstituted solution stability to 4–6 weeks at 2–8°C. Do not vortex or shake; swirl gently until the lyophilised powder dissolves. Rotate injection sites (abdomen, thigh, upper arm) weekly.
Use the RetaLABS reconstitution calculator for custom concentrations. For full storage guidance, see the Peptide Reconstitution & Storage Guide.
Tirzepatide vs Other GLP-1 Compounds: Research Selection
Tirzepatide's position in the GLP-1 class research landscape in 2026:
| Comparison | Tirzepatide advantage | Competitor advantage |
|---|---|---|
| vs Semaglutide | Higher weight loss (20.9% vs 14.9%), dual receptor mechanism | Semaglutide: completed cardiovascular outcomes (SELECT), longer follow-up |
| vs Retatrutide | More complete Phase 3 dataset, lower GI AE burden | Retatrutide: higher Phase 2 weight loss (24.2%), GcgR thermogenesis pathway |
Tirzepatide occupies a middle position: superior efficacy and safety data versus semaglutide, but likely to be exceeded in efficacy by retatrutide when Phase 3 data is confirmed. It currently represents the best-balanced option for researchers who want both strong Phase 3 evidence and meaningful efficacy outcomes beyond semaglutide. For detailed comparisons, see Retatrutide vs Tirzepatide and Retatrutide vs Semaglutide.